Home › Immune System and Disorders › Ohio
Immune System and Disorders clinical trials in Ohio
9 studies for Immune System and Disorders are looking for participants at sites in Ohio.
Cities in Ohio
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Strecker Cancer Center-Belpre, Belpre
- Miami Valley Hospital South, Centerville
- Adena Regional Medical Center, Chillicothe
- and 27 more
RecruitingObservational study
All ages · All sexes · Updated Nov 4, 2026 · NCT04242095A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Cleveland Clinic, Cleveland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06722235A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Cleveland Clinic, Cleveland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06948318CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Cleveland Clinic, Cleveland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT03328078A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07192471Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of Cincinnati (UC) Physicians Company, LLC, Cincinnati
- Cleveland Clinic, Cleveland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05826535Abatacept for the Treatment of Giant Cell Arteritis
- Cleveland Clinic, Cleveland
RecruitingPhase 3
Ages 50 and older · All sexes · Updated Aug 20, 2026 · NCT04474847A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 9, Columbus
- Inmagene Site 5, Mayfield Heights
RecruitingPhase 2
Ages 18 to 74 · All sexes · Updated Aug 12, 2026 · NCT07037901A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- Cleveland Clinic, Cleveland
- The Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 15, 2025 · NCT06619561From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.